PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Optimistic Buy Rating for Jazz Pharmaceuticals Amidst Short-term Challenges and Long-term Growth Potential Jazz Pharmaceuticals Balances Growth and Challenges in Earnings Call PremiumThe FlyJazz Pharmaceuticals price target lowered to $166 from $183 at Morgan Stanley Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts Positive Outlook for Jazz Pharmaceuticals: Buy Rating Affirmed Amid Strategic Moves and Upcoming Catalysts PremiumThe FlyJazz Pharmaceuticals cuts FY25 adjusted EPS view to $4.00-$5.60 Jazz Pharmaceuticals reports Q1 adjusted EPS $1.68 vs. $2.63 last year Jazz Pharmaceuticals backs FY25 revenue view $4.15B-$4.4B, consensus $4.29B 
